The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Vaccines and Biologics: What Rheumatologists Need to Know

Vaccines and Biologics: What Rheumatologists Need to Know

December 1, 2014 • By Kurt Ullman

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Vaccines should ideally be given before starting treatment with Rituximab (RTX). If severity of the disease or other variables makes this impossible, vaccines should be given no sooner than six months after the start of the medicine and no less than four weeks before the next course is scheduled.

You Might Also Like
  • Tips, Resources to Help Rheumatologists Educate Patients on Biologics and Biosimilars
  • ACR/ARHP Annual Meeting 2012: Immunosuppressed Rheumatic Disease Patients Still Candidates for Vaccines
  • EULAR 2014: Non-Tumor Necrosis Factor Biologics Update
Explore This Issue
December 2014
Also By This Author
  • Mouse Research Suggests the Microbiome Is Related to Lupus

“Although there is no data, this approach may also apply for other B cell depleting or targeting treatment regimens,” Dr. Isenberg wrote in the article. “Vaccines can be administered during treatment with anti-tumor necrosis factor (anti-TNF) agents.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The authors’ review of the literature leads them to suggest that the influenza and pneumococcal vaccine should be administered as they are in the general population. They also call for use of tetanus toxoid per normal guidelines. The one exception would be in those who have been treated with RTX within the previous 24 weeks. In this group, passive immunization with tetanus immunoglobulin would be indicated.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

One of the most important aspects of the review is that it also points out what we don’t know. Identifying and addressing these areas can be as important as setting out what is known.

Current Controversies

There is currently some controversy about the use of live-attenuated vaccines (LAVs). Guidelines now in force suggest that LAVs should not be given to anyone being treated with biologics. Drs. Isenberg and Ferreira suggest that patients on immunomodulators should not receive measles, mumps and rubella vaccines or LAVs for influenza, varicella-zoster, yellow fever, and rotavirus vaccines. For most patients in North America, the main issue would be with protection from shingles via zoster. In most other cases, there are nonattenuated substitutes readily available.

It’s important to complete a thorough assessment of vaccination status before beginning the biologic regimen.

“The edict against live vaccines in this population has no real evidence to support it,” says Jeffrey R. Curtis, MD, William J. Koopman Endowed Professor in Rheumatology and Immunology at the University of Alabama at Birmingham. “The current prohibition is largely the result of the Centers for Disease Control and Prevention [CDC] being appropriately conservative because it could be dangerous.”

Since the CDC statement, there have been multiple studies and a growing evidence base suggesting that this may not be as much of a concern as originally thought. Dr. Curtis points to a trial of HIV patients who were given the zoster vaccine in which no safety concerns were raised. He is involved with a new study funded by the ACR and National Institutes of Health that just began enrolling patients and may help better define these issues in those with rheumatic diseases.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 4 | Single Page

Filed Under: Biologics & Biosimilars, Drug Updates Tagged With: Biologics, Immune System, interaction, Research, Rheumatic Disease, rheumatologist, rheumatology, rituximab, Ullman, vaccinesIssue: December 2014

You Might Also Like:
  • Tips, Resources to Help Rheumatologists Educate Patients on Biologics and Biosimilars
  • ACR/ARHP Annual Meeting 2012: Immunosuppressed Rheumatic Disease Patients Still Candidates for Vaccines
  • EULAR 2014: Non-Tumor Necrosis Factor Biologics Update
  • Newer Biologics for RA on Par with TNF-Inhibitors for CV Risk

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)